Drug Trial Radar · NCT02654587
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
219
Actual
Start
Feb 12, 2016
Primary completion
Jan 15, 2021
Study completion Jan 15, 2021
Sponsor
- Lead sponsor
- OSE ImmunotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this clinical trial was to determine if the therapeutic cancer vaccine OSE2101 (TEDOPI) was more effective than standard chemotherapy (docetaxel or pemetrexed) in treating HLA-A2 positive patients with metastatic NSCLC who progressed after sequential or concurrent chemotherapy and immune checkpoint inhibitor given in first or second-line treatment. The main questions were to compare the survival, the tolerance to treatment and the quality of life of patients between the two arms of treatment (OSE2101 versus standard chemotherapy)
Conditions
- Non Small Cell Lung Cancer
Interventions
OSE2101Biological
DocetaxelDrug
PemetrexedDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Approx. 24 months
Locations
78 sites in 10 countries. Site status is shown where the registry gives one.
East Valley Hematology and Oncology medical Group
Burbank, California
Georgetown University Hospital
Washington D.C., District of Columbia
BRCR Medical Center, Inc
Boca Raton, Florida
Pontchartrain Cancer Center
Covington, Louisiana
Meyer Cancer Center, Weill Cornell Medecine
New York, New York
Gabrail Cancer Center Research
Canton, Ohio
Stephenson Cancer Center
Oklahoma City, Oklahoma
Robert W. Franz Cancer Center
Portland, Oregon
Gesinger Medical Center
Danville, Pennsylvania
Millenium Oncology
Houston, Texas
Nemocnice Jihlava, Onkologické oddelení
Jihlava, Czechia
Všeobecná Fakultní nemocnice
Prague, Czechia
Institut Saint Catherine
Avignon, France
Hôpital Avicenne
Bobigny, France
Institut Bergonié
Bordeaux, France
CHGU Morvan - Brest
Brest, France
Hôpital Louis Pradel
Bron, France
Centre Hospitalier de Cholet
Cholet, France
Hôpital intercommunal de Créteil
Créteil, France
CHU Grenoble
Grenoble, France
Clinique Victor Hugo
Le Mans, France
Centre Hospitalier du Mans
Le Mans, France
Hopital Albert Calmette
Lille, France
Paoli-Calmettes Institute
Marseille, France
CHU Montpellier
Montpellier, France
Hôpital Emile Muller
Mulhouse, France
Centre Catherine de Sienne
Nantes, France
Hôpital Saint-Louis
Paris, France
Hôpital Bichat - Claude-Bernard
Paris, France
Hôpital Tenon
Paris, France
Hôpital d'Instruction des Armées Bégin
Saint-Mandé, France
CHU de Strasbourg - Hôpital Civil
Strasbourg, France
Hôpital Larrey - CHU de Toulouse
Toulouse, France
Centre Hospitalier Régional Universitaire de Tours
Tours, France
Centre Hospitalier Troyes
Troyes, France
Institut Gustave Roussy (IGR)
Villejuif, France
Krankenhaus Mehrheit - Kliniken der Stadt Köln - Lungenklinik
Cologne, Germany
Klinik für Innere Medizin II Hospital Martha-Maria Halle-Dölau gGmbH
Halle, Germany
Universitätsklinikum Tübingen Medizinische Klinik II
Tübingen, Germany
Klinik für Innere Medizin II Universitätsklinikum Ulm
Ulm, Germany
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.